TCGA-NJ-A55O-01A-11R-A262-07
— · cohortA2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA2
- subtype
- cohortA2
- age_years
- 56
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- COAGULATION+0.350
- KRAS_SIGNALING_DN+0.320
- PANCREAS_BETA_CELLS+0.310
- MYOGENESIS+0.270
- KRAS_SIGNALING_UP+0.260
- BILE_ACID_METABOLISM+0.240
- ESTROGEN_RESPONSE_EARLY+0.230
- ESTROGEN_RESPONSE_LATE+0.210
- COMPLEMENT+0.190
- INFLAMMATORY_RESPONSE+0.150
Top 10 suppressed
- E2F_TARGETS-0.690
- MYC_TARGETS_V1-0.670
- G2M_CHECKPOINT-0.620
- MYC_TARGETS_V2-0.590
- DNA_REPAIR-0.520
- MTORC1_SIGNALING-0.460
- UNFOLDED_PROTEIN_RESPONSE-0.440
- MITOTIC_SPINDLE-0.360
- PI3K_AKT_MTOR_SIGNALING-0.330
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E9-A3Q9-01A-11R-A21T-07 | — | B | 0.944 |
| 2 | TCGA-97-7941-01A-11R-2187-07 | — | cohortA1 | 0.910 |
| 3 | TCGA-97-8552-01A-11R-2403-07 | — | cohortA1 | 0.909 |
| 4 | TCGA-91-8497-01A-11R-2403-07 | — | cohortA1 | 0.904 |
| 5 | TCGA-97-A4M2-01A-12R-A24X-07 | — | cohortA1 | 0.902 |
| 6 | TCGA-67-4679-01B-01R-1755-07 | — | cohortA1 | 0.892 |
| 7 | BS_AKRHBPNZ | Ganglioglioma | — | 0.888 |
| 8 | TCGA-62-8397-01A-11R-2326-07 | — | cohortA1 | 0.887 |
| 9 | BS_NT9NZYFD | Ganglioglioma | — | 0.887 |
| 10 | BS_DV86M0Y7 | pilocytic astrocytoma | — | 0.885 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| COAGULATION | 0.350 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.320 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.310 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.270 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.260 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.240 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.230 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.210 | Idelalisib | — uncovered |
| COMPLEMENT | 0.190 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.150 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.130 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.130 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.120 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.040 | Inavolisib | — uncovered |